Mineralys Therapeutics Inc
mineralystx.comWhat Do They Do?
Develops lorundrostat, an oral medicine for hypertension and related conditions such as chronic kidney disease and sleep apnea, for patients with these conditions.
10-K for FY2025, filed Mar 12, 2026We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$241.1MView ↗
- ▲ +457% (Loss)
- vs −$43.3M in Q2 FY2025
Who Do They Compete With?
Competes with AstraZeneca, Boehringer Ingelheim, Damian Pharma, CORXEL, Roche, Alnylam, Idorsia, Ionis, Bayer, Daiichi Sankyo, Azurity, and George Medicines
10-K for FY2025, filed Mar 12, 2026companies working to develop ASIs, including AstraZeneca, Boehringer Ingelheim, Damian Pharma, and CORXEL; companies commercializing or…View ↗
Loading...
